FibroGen, Inc. (FGEN)

Market Cap	31.67M
Revenue (ttm)	29.62M
Net Income (ttm)	-47.58M
Shares Out	100.92M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,284,489
Open	0.3362
Previous Close	0.3280
Day's Range	0.3030 - 0.3418
52-Week Range	0.1800 - 2.3980
Beta	0.83
Analysts	Strong Buy
Price Target	10.00 (+3,086.74%)
Earnings Date	Mar 17, 2025

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 14, 2014
• Employees: 225
• Stock Exchange: NASDAQ
• Ticker Symbol: FGEN
• Website: https://www.fibrogen.com

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Analyst Forecast

According to one analyst, the rating for FGEN stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(3,086.74% upside)

Analyst Consensus: Strong Buy